The European Commission granted marketing authorization to Epidyolex, the trade name in Europe for Epidiolex, GW Pharmaceuticals announced Monday. In June 2018, the U.S. Food and Drug Administration approved Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older. The CBD-based medicine was greenlighted in Europe […]
European Commission approves Epidiolex marketing authorization, GW Pharmaceuticals says is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs
Read More: European Commission approves Epidiolex marketing authorization, GW Pharmaceuticals says
Comments are closed, but trackbacks and pingbacks are open.